Skip to main content

Remote Job Finders (RJF)

TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push that number even higher.

How Abogen went from COVID hype to a $7.8B Novartis deal

After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.

Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart

Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.

Beyond equity: Why venture debt is reshaping European biotech

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Scroll to top